Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy
B Song, P Yang, S Zhang - Cancer Communications, 2024 - Wiley Online Library
Cancer is a leading cause of death worldwide. Targeted therapies aimed at key oncogenic
driver mutations in combination with chemotherapy and radiotherapy as well as …
driver mutations in combination with chemotherapy and radiotherapy as well as …
Targeting misfolding and aggregation of the amyloid-β peptide and mutant p53 protein using multifunctional molecules
L Grcic, G Leech, K Kwan, T Storr - Chemical Communications, 2024 - pubs.rsc.org
Biomolecule misfolding and aggregation play a major role in human disease, spanning from
neurodegeneration to cancer. Inhibition of these processes is of considerable interest, and …
neurodegeneration to cancer. Inhibition of these processes is of considerable interest, and …
Altering relative metal-binding affinities in multifunctional Metallochaperones for mutant p53 reactivation
K Kwan, O Castro-Sandoval, B Ma, D Martelino… - Journal of Inorganic …, 2024 - Elsevier
The p53 protein plays a major role in cancer prevention, and over 50% of cancer diagnoses
can be attributed to p53 malfunction. p53 incorporates a structural Zn site that is required for …
can be attributed to p53 malfunction. p53 incorporates a structural Zn site that is required for …
Comparative molecular dynamics simulation of apo and holo forms of the P53 mutant C176F: a structural perspective
R Hephzibah Cathryn… - Journal of Taibah …, 2024 - Taylor & Francis
Zinc fingers represent a highly diverse structural domain, with P53 being a notable example
among zinc-dependent transcription factors. The folding patterns of proteins in the cell are …
among zinc-dependent transcription factors. The folding patterns of proteins in the cell are …
[HTML][HTML] Anticancer therapeutic strategies for targeting mutant p53-Y220C
V Chasov, D Davletshin, E Gilyazova… - Journal of Biomedical …, 2024 - ncbi.nlm.nih.gov
The tumor suppressor p53 is a transcription factor with a powerful antitumor activity that is
controlled by its negative regulator murine double minute 2 (MDM2, also termed HDM2 in …
controlled by its negative regulator murine double minute 2 (MDM2, also termed HDM2 in …
Unmet Horizons: Assessing the Challenges in the Treatment of TP53-Mutated Acute Myeloid Leukemia
C Stafylidis, D Vlachopoulou… - Journal of Clinical …, 2024 - mdpi.com
Acute myeloid leukemia (AML) remains a challenging hematologic malignancy. The
presence of TP53 mutations in AML poses a therapeutic challenge, considering that …
presence of TP53 mutations in AML poses a therapeutic challenge, considering that …
cfDNA-Diagnostik als Therapie-Monitoring für Patienten mit Adenokarzinomen des gastroösophagealen Übergangs in perioperativer oder palliativer Behandlung
J Schmiederer - 2024 - oparu.uni-ulm.de
Anlässlich des Weltkrebstags am 4. Februar 2020 warnte die Weltgesundheitsorganisation
vor einem weltweiten Anstieg von Tumorerkrankungen in Höhe von rund 60 Prozent in den …
vor einem weltweiten Anstieg von Tumorerkrankungen in Höhe von rund 60 Prozent in den …
[PDF][PDF] cfDNA-Diagnostik als Therapie-Monitoring für Patienten mit Adenokarzinomen des gastroösophagealen Übergangs in perioperativer oder palliativer …
T Seufferlein - oparu.uni-ulm.de
G2 Mäßig differenziert G3 Schlecht differenziert G4 Nicht differenziert HER2 Human
epidermal growth factor receptor 2 ID Identifikationsnummer IGF Insulin-like-growth factor …
epidermal growth factor receptor 2 ID Identifikationsnummer IGF Insulin-like-growth factor …
[引用][C] cfDNA-Diagnostik als Therapie-Monitoring für Patienten mit Adenokarzinomen des gastroösophagealen Übergangs in perioperativer oder palliativer …
J Schmiederer - Dissertation, Ulm, Universität Ulm …